There have been a few studies discussing the potential oncogenic role of AMACR in prostate adenocarcinomas [38,39], so in conjunction with its strong association with PTEN homogeneous loss, it could prove to be an important candidate biomarker for prostate cancer progression and prognosis apart from its well-established diagnostic significance. The gene discussed is PTEN; the disease is prostate carcinoma.